Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

External xenoliths vaccine combined dendritic cell cytokine induced killer (DC-CIK) new technology for cancer therapy

A DC-CIK, tumor treatment technology, applied in anti-tumor drugs, drug combinations, antibody medical components, etc., can solve the problems of poor prognosis of tumor patients and high recurrence rate of cancer cells, and achieve strong killing effect and strong tumor antigen delivery. effect and provide quality of life

Inactive Publication Date: 2013-10-30
孙勇
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the prognosis of tumor patients is still poor, and its 5-year survival rate is only about 50%, mainly due to the high recurrence rate caused by residual cancer cells after treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0007] Through this example to illustrate the technology of the present invention, the vaccine prepared by using the patient's own DC to secrete outosomes, combined with DC and related cytokines to induce CIK cells, reinfused or injected into the patient's body, so as to prevent tumor recurrence and metastasis . The operating steps of the present invention are as follows:

[0008] (1) Preparation of DC cells. Hepatitis (HAV, HBV, HCV, HDV, and HEV) and viruses (HIV-1 / 2, Treponema pallidum, cytomegalovirus, and parasites) are tested for tumor patients before blood collection, and autoimmune diseases are excluded at the same time. Under certain conditions, the patient's autologous peripheral blood mononuclear cells (peripheral blood mononuclean cells, PBMC) were collected, and the number reached 2.0X10 8 above. Under the condition of GMP100 grade, half of PBMC mononuclear cells were collected in serum-free medium (containing SCF, TPO, G-CSF, GM-CSF, IL-1, IL-3, methylcellulos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an external xenoliths vaccine combined dendritic cell cytokine induced killer (DC-CIK) new technology for cancer therapy. Cancer autologous peripheral blood is utilized, mononuclear leucocyte is separated and purified by using a level-100 good manufacturing practice (GMP) workshop, a part of mononuclear leucocyte is induced and differentiated to be dendritic cell (DC), and external xenoliths (EXO) in supernate is collected; and the other part of mononuclear leucocyte is induced into cell factor induced CIK; and DC and CIK are co-cultured simultaneously; and after quality testing passes, cancer patients are actively and passively immunized. EXO is a novel acellular vaccine, so that the EXO is safe, effective, stable and practical; and DC-CIK co-culture has a coordination antineoplastic effect, and costimulatory molecule expression promoting DC is increased; and therefore, cancer treatment through the external xenoliths vaccine combined DC-CIK is a good method for preventing relapse and metastasis of cancers.

Description

technical field [0001] The present invention utilizes exocysts, DC cells and monocytes secreted by the patient's own dendritic cells (DC) to prepare an exocytic vaccine combined with DC and related cytokine-induced killer cells (CIK) for tumor treatment. It involves the fields of basic medicine, biopharmaceuticals and tumor treatment science. Background technique [0002] Cancer has become the number one killer of human beings. According to statistics, there are about 12.7 million new cases and 760 deaths in the world every year, and the number is increasing year by year. Clinical treatment is mainly based on surgery, radiotherapy and chemotherapy, and considerable therapeutic effects have been achieved, which greatly improves the survival rate of tumor patients and prolongs the survival period. However, the prognosis of cancer patients is still poor, and the 5-year survival rate is only about 50%, mainly due to the high recurrence rate caused by residual cancer cells after...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K35/14A61P35/00C12N5/0783C12N5/0784
Inventor 孙勇
Owner 孙勇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com